Jul. 01, 2026

​5,200+ High-Impact Publication Evidence | ExCell Bio Fetal Bovine Serum Directly Unlocks 7 CNS Top-Tier Journals in the First Half of 2026

5,200+ High-Impact Publication Evidence | ExCell Bio Fetal Bovine Serum Directly Unlocks 7 CNS Top-Tier Journals in the First Half of 2026

On June 10, 2026, the research group led by Professor Du Peng from the School of Life Sciences at Peking University published an online research paper titled "Continuous modeling of primate embryogenesis from totipotency to early organogenesis" in Cell. This study achieved long-term stable culture of cynomolgus totipotent blastomere-like cells (cTBLCs) and, using this as a breakthrough, established an embryo-like culture system that recapitulates key processes of primate embryonic development from a totipotent-like state to early organogenesis in vitro.

企业微信截图_1782809033242.png

From the stable passaging of cTBLC totipotent stem cells and the construction of three-dimensional blastocysts to the long-term culture of gastruloids, neural tubes, and beating cardiac tube organoids, the entire cell culture system consistently used ExCell Bio FSP500 Uruguay Premium Fetal Bovine Serum throughout the process. With stable lot consistency and excellent cell activity performance, the serum provided important product assurance for the study, powerfully demonstrating the outstanding performance and global influence of high-quality domestic brand fetal bovine serum.

企业微信截图_17828087988712.png

Partial Showcase of High-Impact Literature Using ExCell Bio Fetal Bovine Serum in H1 2026

ExCell Bio fetal bovine serum has accumulated cumulative sales of over 650,000 bottles, with customers spanning antibody drugs, cell and gene therapy, vaccines, and basic research. It has established deep collaborations with the TOP10 biopharmaceutical companies in China, helping tens of thousands of scientists scale new heights in research. As of the latest statistics, SCI articles citing ExCell have exceeded 5,200+, with the highest impact factor reaching 81.2. ExCell has become the preferred choice for researchers through its strong capabilities.

识别文字并翻译为英文版本.png

In H1 2026, we received many "article reward applications" from faculty members. We would first like to congratulate these hardworking teachers and students who have remained at the front line, dedicated themselves to research, worked silently, continuously innovated and tackled challenges, and reaped fruitful results.

Article Title

Journal Name

Product Catalog Number

A broadly protective antibody targeting gammaherpesvirus gB

Nature

FSP500

NINJ1 regulates plasma membrane fragility under mechanical strain

Nature

FSP500

Subnucleosome preference of human chromatin remodeller SMARCAD1

Nature

FSP500

Family single-cell atlases reveal pig pregnancy and fetal growth restriction critical cell types

Science

FNA500

Rational Design of Gi-biased CB1 agonist with reduced side effects

Cell

FSP500

CLIM-TIME identifies metastatic microenvironment modulators for T cell therapy response

Cell

FSP500

Continuous modeling of primate embryogenesis from totipotency to early organogenesis

Cell

FSP500

TOPK Suppresses the CD8+ T Cell Antitumor Immunity via Modulation of IRF5 Expression

Cancer Communications

FSP500

WDR5 remodels NANOG condensates to drive transcriptional programs and sustain stem cell identity

Nature Communications

FSP500

CD168 Identifies Proliferating Pancreatic Islet Cells in Murine and Human

Advanced Science

FSD500

Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia–reperfusion lung injury and pneumonia

Bioactive Materials

FSP500

Our Products

About Cookies on This Site

We use cookies to allow our website to function properly, personalize content and advertising, provide social media features, and analyze traffic. We also share information about your use of our website with social media, advertising, and analytics partners. If you would like to accept all optional cookies, please select "Accept all". To learn more about our privacy policy and how we use cookies, please visit the Privacy Policy page.